Ignite Creation Date:
2024-05-05 @ 11:55 AM
Last Modification Date:
2024-10-26 @ 9:16 AM
Study NCT ID:
NCT00171860
Status:
TERMINATED
Last Update Posted:
2012-05-01
First Post:
2005-09-13
Brief Title:
A Study to Determine the Safety and Efficacy of Imatinib Mesylate in Patients With Idiopathic Hypereosinophilic Syndrome
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis
Study Overview
Official Title:
A Study to Determine the Safety and Efficacy of Imatinib Mesylate in Patients With Idiopathic Hypereosinophilic Syndrome
Status:
TERMINATED
Status Verified Date:
2012-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The objectives of the study are
1 Evaluation of the safety profile of imatinib mesylate in patients with idiopathic hypereosinophilic syndrome resistant or refractory to or intolerant of prednisone hydroxyurea or interferon-alpha or untreated patients carrying the Fip1L1-PDGFRA fusion protein
2 Evaluation of the efficacy of imatinib mesylate in patients with idiopathic hypereosinophilic syndrome
3 Analysis of patients blood samples for the detection of activated kinases
1 Evaluation of the safety profile of imatinib mesylate in patients with idiopathic hypereosinophilic syndrome resistant or refractory to or intolerant of prednisone hydroxyurea or interferon-alpha or untreated patients carrying the Fip1L1-PDGFRA fusion protein
2 Evaluation of the efficacy of imatinib mesylate in patients with idiopathic hypereosinophilic syndrome
3 Analysis of patients blood samples for the detection of activated kinases
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None